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Pericytes are cells located inside the basement membrane of blood vessels. They play 
an essential role in angiogenesis as well as in vessel maintenance and stabilization. 
Recently it has been found that pericytes from various tissues demonstrated features 
of mesenchymal stem cells (MSCs). It has thus been proposed that some pericytes 
may be MSCs residing in a perivascular niche and serving as a progenitor reserve for 
tissue regeneration in response to injury by differentiation into other lineages. In this 
study, we hypothesized that apart from possessing MSC-like characteristics, pericytes 
further possess angiogenic functions that conventional MSC cannot substitute for. To 
verify if commercially purchased placenta pericytes are truly MSC-like, the 
expression of pericytes, MSCs, and fibroblasts (negative control) of the MSC antigen 
profile was compared. It was found that the marker expressions profile of all three 
cell types all fulfilled the marker panel required of MSCs. Interestingly, CD146, the 
surface marker which is used to isolate pericytes from various tissues, was expressed 
by all three cell types. To conclude, a conventional MSC marker profile is not 
sufficient to identify MSC. Therefore we further investigated the differentiation 
potential of the three cell types and found that only pericytes and MSCs were capable 
of adipogenesis and osteogenesis, indicating that pericytes as MSC are multipotent. 
Once we were able to show that pericytes behave like MSC, we posed the question if 
pericytes are more than just MSC. The three cell types were therefore compared for 
pericytic features. It was found that pericytes expressed NG2, desmin and Tie2, 
which are pericytic markers linked to important functions in angiogenesis that MSCs 
and fibroblasts do not share. As CD146 is not selective for the pericytes we propose a 
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new set of potential markers, which will have to be verified in the isolation of 
pericytes. The in vitro pro-angiogenic ability of pericytes, MSCs, and fibroblasts were 
also investigated using a Matrigel
TM
 assay, and it was observed that pericytes, MSCs 
and fibroblasts all co-localized with endothelial cell networks. However, MSCs and 
fibroblasts contracted the network in a cell-ratio dependent manner. These findings 
suggested that pericytes are truly MSC-like cells, with additional role in angiogenesis 
distinct from that of MSCs.  
In conclusion, the traditionally employed in vitro method to identify pericytes by the 
co-localization of cells with tubular network on Matrigel
TM
 is inconclusive and not 
sufficient. In order to distinguish pericytes from other cells in the tube formation 
assay pericyte and non-pericyte standards have to be considered and the contraction 
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1. Background: MSCs and pericytes —interweaving 
identities 
Mesenchymal stem/stromal cells (MSCs) have been under the spotlight of stem cell 
therapy because of its multi-lineage differentiation capacity (reviewed by Ankrum, et 
al., 2010), immunosuppressive effect (Nauta, et al., 2007), and increasingly 
importantly, its ability to secret trophic factors that induce tissue regeneration 
(reviewed by Ankrum, et al., 2010). According to the US Public Clinical Trials 
Database (U. S. National Institutes of Health, 2012), there is nearly 300 clinical trials 
exploiting MSCs for their therapeutic values. Most of the current clinical trials target 
diabetics, ischemia, myocardial infarction, inflammation, and immune diseases. The 
trial outcomes, on the other hand, are encouraging but not yet satisfactory. Implanted 
or infused MSCs often have low efficacy in vivo. It is reasoned that the improvement 
of MSC therapy is hindered by the limited understanding of MSC cell fate in vivo 
(reviewed by Ankrum, et al., 2010). The consensus on MSC identification is solely 
based on its marker expression and differentiation potential under in vitro conditions 
(Augello, et al., 2010; Dominici, et al., 2006). Although MSC in vitro characteristics 
are intensively researched upon, their in vivo counterpart still remains to be found  
(reviewed by Corselli, et al., 2012). 
A few discoveries in recent years provide hints on the in vivo niche of MSCs. The 
first piece of evidence comes from the successful isolation of MSC from a wide 
spectrum of tissues. Conventionally extracted from bone marrow, MSCs have now 
been isolated from virtually all postnatal connective tissues, such as the adipose 
tissue, dental pulp, and so on (reviewed by Bianco, et al., 2008; da Silva Meirelles, et 
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al., 2006). These studies suggest that the in vivo source of MSC must be widely 
distributed across different tissues and organs.  
Following this line of thought, several research groups have come up with the 
hypothesis that the in vivo MSC reservoir is most likely to be associated with the 
blood vessels, which is present in all tissues in the body. More specifically, they 
propose that MSCs in situ are perivascular. To prove this theory, perivascular cells 
have been isolated and purified by flow cytometric cell sorting. The sorted cells were 
shown to display a MSC marker profile, and to demonstrate adipogenic (Crisan, et al., 
2008; Corselli, et al., 2012; Zannettino, et al., 2008), osteogenic (Sacchetti, et al., 
2007; Crisan, et al., 2008; Corselli, et al., 2012; Zannettino, et al., 2008), 
chondrogenic (Corselli, et al., 2012; Zannettino, et al., 2008), and even myogenic 
potentials (Crisan, et al., 2008; Dellavalle, et al., 2007). Therefore, perivascular cells 
are shown to be bona fide MSCs. Some even go so far as to pose the question that if 
all MSCs are pericytes (Caplan, 2008). 
Under such circumstances, pericytes, one of the perivascular cells and are found 
around small blood vessels (Gaengel, et al., 2009), have attracted great research 
interest. Until recently, pericytes have been a cell type that is not well studied and 
understood. They have been shown to play an essential role in the maturation and 
stabilization of blood vessels (Armulik, et al., 2005). The recent evidences on their 
additional function as MSC-like progenitor cells (reviewed by Crisan, et al., in press) 
put them under new attention as candidates for cell therapy and regenerative 
medicine. These cells, not only multipotent but also have pro-angiogenesis properties, 
may become a promising alternative for MSC in stem cell therapy. Also, the study on 
11 
 
the relationship between pericytes and MSCs may shine light on the obscure in vivo 
identity of MSC.  
However, the identification of pericytes is no easier problem. Different from MSCs, 
pericytes are traditionally identified not by their in vitro characteristics, but by their in 
vivo location. Pericytes are defined as cells located within the basement membrane of 
endothelial cells. This is until now the ultimate standard for pericyte identification, 
which is unfortunately impractical and sometimes impossible to verify for in vitro 
cultures. Besides the definition, pericyte identification is further complicated by its 
heterogeneity. Pericytes are widely distributed around virtually all small blood 
vessels in the body, and their maker expression depends on their tissue of origin as 
well as degree of maturation of the associated blood vessels (reviewed by Bergers, et 
al., 2005).  To date, there is no marker or combination of markers that is available for 
identification of pericytes from all tissues reviewed by (Armulik, et al., 2011). A 
vigorous study that claims to have isolated pericytes by a set of markers would often 
verify the in vivo location of the cells in their tissue of origin. 
Most of the recent studies on pericyte-MSC relationship concentrate on flow 
cytometric sorting isolated pericytes, and their in vivo or in vitro characterization for 
MSC-specific features (Péault, et al., 2007; Crisan, et al., 2008; Covas, et al., 2008; 
Castrechini, et al., 2010; Corselli, et al., 2012). Side by side comparison of MSCs and 
pericytes are rare. For example, few papers have been published on comparing MSCs 
and pericytes from the same bone marrow source (reviewed by Bouacida, et al., 
2012). However, such comparative assays are essential for finding out the differences 
and similarities of the two cell populations.   
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This study thus proposes an unbiased comparison between a typical pericyte 
population (pericytes from human placenta isolated by CD146 expression, Promocell) 
and a typical MSC population (MSCs isolated from human bone marrow by plastic 
adherence, Lonza) for MSC as well as pericyte related characteristics. In this way, 
this study aims to generate novel insights on several elusive aspects of the MSC-
pericyte relationship: 
The first motivation of the study is to address the unanswered question: are MSCs 
really pericytes? Although pericytes have been shown to possess the major 
characteristics of MSC (Crisan, et al., 2008; Dellavalle, et al., 2007; Shi, et al., 2003; 
Zannettino, et al., 2008; Díaz-Flores, et al., 2009), the reverse question is rarely 
posed. Do MSCs possess the typical pericyte features? Pericytes have been shown to 
interact with endothelial cells through a number of pathways, and to play a specific 
role in angiogenesis and blood vessel maintenance (Bergers, 2008; Bergers, et al., 
2005; Hirschi, et al., 1996). These functions are rarely associated with MSCs, and 
would need to be verified before being able to conclude if MSCs are truly pericytes. 
That is why this study chose to test both pericytes and MSCs not only for MSC 
related characteristics, but also pericyte and angiogenesis related features.  
The second motivation of the study is to seek a way to identify pericyte in vitro. By 
screening both pericytes and MSCs for a spectrum of marker and functional assays, 
we expect to establish a set of in vitro assays that is sensitive enough to distinguish 
pericytes from other mesenchymal lineages, for example MSCs, if there is any 
differences between the two. Many who claim that they have identified pericytes rely 
on one or a few markers, while to this day there is no pericyte specific/ pan-pericyte 
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marker available (reviewed by Armulik, et al., 2011). It is to be verified if these 
“pericytes”, isolated from various tissues using different sets of markers, refer indeed 
to the same population. The ultimate test still requires verifying the in vivo 
perivascular location of the cells. It would be of great interest to have a set of 
standardized assays that enables identification of pericytes in vitro. Such assays 
would also need to be able to identify functional pericytes, i.e. cells that maintains 
their pro-angiogenic properties and the ability to interact with endothelial cells. This 
would provide a platform to differentiate pericytes from other cell populations in 
vitro. Moreover, it would also allow for standardization of pericytes for research 
purposes as well as for clinical application. 
Besides providing a tool for facilitating future research, a third motivation of the 
study is to obtain insights of the in vivo characteristics of pericytes and MSCs. 
Although the in vivo function and properties of MSCs and pericytes are beyond the 
scope of this study, some clues may be obtained from their in vitro characteristics and 
behaviors.   
1.1 Mesenchymal Stem Cells (MSCs)  
Before moving on to compare the different cell types, it is important to review the 
current definition and methods of identification and characterization for each of them.  
The cell population that is called mesenchymal stem cells today was first described 
by Friedenstein (1968), who found a non-hematopoietic progenitor population in the 
bone marrow that is capable of forming single clones in culture (colony-forming 
units-fibroblastic or CFU-Fs) and is capable to undergo osteogenesis in vitro 
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(Friedenstein, et al., 1970).The term “mesenchymal stem cells”, or MSCs, are later 
made popular by Pittenger et al. (1999), who showed that these plastic adherent, 
colony-forming cells isolated from bone marrow were able to differentiate into 
osteoblasts, adipocytes, and chondrocytes in vitro when induced by a cocktail of 
small molecules. They further suggested that this particular cell population may be 
the reservoir for adult connective tissue regeneration. Nowadays the sources of MSCs 
have been expanded beyond bone marrow. MSCs have been isolated from virtually 
all types of postnatal tissues, such as adipose tissue, dental pulp, and so on (reviewed 
by Bianco, et al., 2008; da Silva Meirelles, et al., 2006). The in vivo location of MSCs 
still remains to be confirmed, which is difficult due to the lack of a MSC-specific 
marker set (reviewed by Bianco, 2011).  
One of the currently most accepted definition of MSCs is proposed by the 
International Society for Cellular Therapy (ISCT) (Dominici, et al., 2006), who 
suggested three minimal conditions for a cell population to be called MSCs. Firstly, 
the cells have to be plastic adherent, Secondly, they should be positive for surface 
antigens CD105, CD73, CD90, and at the same time be negative for CD45, CD34, 
CD14 or CD11b, CD79α or CD19, and HLA-DR. Lastly, they should be able to 
differentiate in vitro into three mesenchymal lineages, namely osteoblasts, adipocytes, 
and chondrocytes, under standard differentiation conditions. 
Recent years have seen a shift of interest in the clinical application of MSCs. MSCs 
were initially regarded as the earliest progenitor cells in mesenchymal lineage 
(Caplan, 1994). The earlier studies focused on their ability to self-renew and to 
differentiate into multiple mesenchymal lineages, and tried to explore their 
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therapeutic potential for tissue repair or even for gene therapy (Bonab, et al., 2006). 
Mesenchymal stem cells from bone marrow have already been used for clinical 
applications (Gerson, 1999).  It has been since observed that MSC implantation 
resulted somehow in reduced inflammation, fibrosis and apoptosis, even when there 
is a lack of effective MSC differentiation in situ  (reviewed by Ankrum, et al., 2010; 
Bianco, 2011). Systematically infused auto- or allogeneic MSCs were able to home to 
damaged tissues and to establish a conductive microenvironment for tissue 
regeneration. It has thus been suggested that other factors than differentiation and 
proliferation must be contributing to the therapeutic effect of MSC in clinical trials. 
However, the actual mechanism of the effect of MSCs in vivo is still unclear. 
(Ankrum, et al., 2010; Caplan, 2007; Bianco, 2011) 
Although numerous clinical trials are ongoing to exploit the therapeutic effect of 
MSCs, few have proved to be significantly effective. It has been suggested that the 
current bottleneck of MSC cell therapy is the lack of understanding of their in vivo 
cell fate (Ankrum, et al., 2010). The dilemma is that the definition and 
characterization of MSCs have depended exclusively on in vitro cultures, leaving the 
in situ identity and behavior of these cells elusive (Bianco, 2011).  
Even the nomenclature of MSC is now being challenged. The use of “stem cells” is 
considered not vigorous. MSCs only have limited renewing ability in vitro. 
Furthermore, proliferation and differentiation in culture do not necessarily mean self-
renewal and multi-potency in vivo (Bianco, 2011). The word “mesenchymal” is also 
often debated, since muscle and bone are derived from different progenitors during 
the early embryonic development (Bianco, 2011; Nombela-Arrieta, et al., 2011) 
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Therefore, the search of the in vivo counterpart of MSC is an important ongoing 
research topic both for elucidating on the identity of MSCs as well as for improving 
the clinical outcome of MSC-based therapy. Pericytes, with numerous features shared 
with MSCs, may promise to provide valuable clues on the subject.   
1.2 Pericytes  
The discovery of pericytes is attributed to the French scientist Charles Rouget in 
1873. They carried thus the name "Rouget cells". The term "pericytes" was first 
coined by Zimmermann in 1923, referring to their close association with endothelial 
cells (Armulik, et al., 2011; Hirschi, et al., 1996). The definition of pericytes has since 
depended heavily on the in vivo location of the cells relative the endothelial cells. 
Pericytes are originally defined as extensively branched cells located in non-muscular 
microvessels, capillaries and postcapillary venules (Díaz-Flores, et al., 2009). The 
currently accepted and most vigorous definition of pericytes is cells that are located 
within the basement membrane of blood vessels, which come from the electron 
microscopy observation of pericytes in situ (reviewed by Sims, 1986).   
In the vasculature system, pericyte is one of the two categories of mural cells that are 
found around blood vessels (Figure 1). In specific, pericytes are found around small 
blood vessels. They wrap the selves around the inner single-layer vessel lumen 
formed by endothelial cells (EC). Pericytes are in physical contact with EC and have 
intimate interactions with the EC-formed vessels (McDonald, 2008). The other type 
of mural cells, smooth muscle cells, is found around large blood vessels. They form 
multiple layers (tunica media) around the endothelial cells-formed vessels (tunica 
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intia). They are further enveloped by the tunica adventitia, which consists of 
fibroblasts and connective tissue (Corselli, et al., 2010). 
 
Figure 1. EC-mural cell interaction (adapted from (Gaengel, et al., 2009)). Blood vessels consist of 
two cell types: endothelial cells (EC, in yellow) which form the internal lumen, and mural cells (in 
green) which wrap around the EC-formed vessels. Under the class of mural cells, there is a sub-
category of cells named pericytes (at lower left corner of the diagram) that are embedded within the 
basement membrane of blood vessels in close association with EC. The interaction and exchange of 
signal molecules between pericytes and EC are essential for the stabilization and maturation of small 
blood vessels. For example, the PDGF-B/PDGFR-β pathway and the Ang1/Tie2 pathway (represented 
by a and b, respectively). 
The prominent feature of pericytes is that they sit in the basement membrane of the 
blood vessels. They are in close contact with the endothelial cell through various 
mechanisms such as gap junction or peg-socket contact (Armulik, et al., 2011; 
Hirschi, et al., 1996).    
1.2.1 Pericyte distribution in tissues  
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Pericytes are widely distributed in the body. Pericytes are found in almost all tissue 
types in blood microvasculature, but not in normal lymphatic system (Armulik, et al., 
2011). The most prominent feature is their close association with endothelial cell 
vessels. Pericytes are located more frequently around microvasculature such as 
capillaries and small venules, as well as pre-capillary arterioles (Sims, 1986). 
Pericytes are often found at the junction points of capillaries or of small vessels and 
capillaries, where they stretch themselves along the length of blood vessels across 
several branches (Armulik, et al., 2011; Bergers, 2008). The EC-pericyte ratio around 
blood vessels is tissue specific. It can vary from 1:1 in retina tissues and down to 
100:1 in human skeletal muscle, for example (reviewed by Díaz-Flores, et al. (2009)). 
Besides the variation in the EC-pericyte ratio, pericyte distribution in tissue also 
varies in the form in which pericytes wrap themselves around EC. They can come in 
the form of single, discontinuous cells to a mono-cell layer around EC-formed vessels 
(Gerhardt, et al., 2003; Hirschi, et al., 1996) 
Pericytes are found also at sprouting blood vessels. EC recruit pericytes during 
angiogenesis by secreting platelet-derived growth factor (PDGF), which promote the 
proliferation and migration of pericytes (Armulik, et al., 2005).  Depletion of 
pericytes through inhibition of platelet-derived growth factor receptor β (PDGFR-β) 
in vivo leads to leaky and dilated vessels in mice as a results of lack of mural cells 
around the blood vessels (Hellström, et al., 2001). 
So far, pericytes have been isolated from a wide spectrum of human tissues, such as 
skeletal muscle, myocardium, placenta, pancreas, skin, brain, and bone marrow 
(Crisan, et al., 2008), Zannettino and colleagues (2008) have isolated multipotent 
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pericyte-like cells from human adult adipose tissues by the markers STRO-1, CD146 
or 3G5. However, it is worth noting that the isolated “pericytes” have a different 
marker profile compared to Crisan’s group, and common pericyte markers, like 
desmin, NG2, PDGFR-β, has not been tested. The markers used for isolation are not 
restricted to small vessels, and the expression of STRO-1 was not exclusively 
perivascular, based on the immunofluorescence staining of frozen sections. Moreover, 
only a small portion of the isolated cells possessed multipotency. The group of Paolo 
Bianco (Dellavalle, et al., 2007) isolated ALP+ CD56- cells from human adult muscle 
that exhibited a typical pericyte marker profile (annexin V, alkaline phosphatase, 
desmin, smooth muscle actin, vimentin and PDGFR-β), though they have weak 
expression for CD90, CD105 and CD146.  It demonstrates that pericytes isolated 
using different markers may have different marker profiles, while those isolated with 
CD146 resemble most that of MSCs.  
1.2.2 Pericyte origin 
Pericytes can develop from a variety of tissues (Lamagna, et al., 2006). For example, 
brain pericytes are shown to originate from neurocrest (Bergwerff, et al., 1998). It has 
also been proposed that VEGFR2+ angioblasts can differentiate into EC or pericytes 
under different stimuli (Yamashita, et al., 2000).  There are also research groups who 
suggested that pericytes originate from myofibroblasts (Díaz-Flores, et al., 2009). It 
has equally been shown that bone marrow derived cells, when systematically infused 
into mice, can home to perivascular locations, infiltrate with microvasculature, and 
express pericytic markers, indicating that some pericytes may also come from the 
bone marrow (Ozerdem, et al., 2005; Rajantie, et al., 2004) 
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Finally, MSCs have as well been proposed as pericyte precursors. It has been shown 
that when co-cultured with endothelial cells, MSCs (10T1/2, ATCC) are able to 
differentiate into pericyte-like phenotype. They expressed NG2 and αSMA, stabilized 
EC formed networks on matrigel, and homed to perivascular locations when 
implanted into mice developing vessels (Darland, et al., 2001; Hirschi, et al., 1998).  
1.2.3 Increasing interest in pericyte research arising from newly discovered 
pericyte functions: an implication for their therapeutic potential  
The research on pericyte function is still ongoing and recent years have seen rapid 
advances in understanding of the role of pericytes in microvascular system. 
Nevertheless, three main pericyte functions have been pointed out. The first function 
of pericyte is the maintenance of blood vessels through secreting growth factors that 
are indispensable for EC survival (Gaengel, et al., 2009; Gerhardt, et al., 2003). Three 
well-known ligand/receptor pairs in EC-pericyte interaction are VEGF/VEGFR, 
PDGF-B/PDGFR-βand Ang1/Tie2. Pericytes are able to produce vascular endothelial 
growth factor (VEGF) which binds to the VEGF receptors in EC. VEGF is essential 
for EC survival and regulates EC immigration (Darland, et al., 2003; Senger, et al., 
1996; Franco, et al., 2011). PDGF-B is important for mural cell recruitment towards 
EC-formed vessels (Hellström, et al., 1999). Inhibition of PDGF-B impaired EC’s 
ability to recruit mesenchymal cells to EC vessels on Matrigel
TM
 in vitro (Hirschi, et 
al., 1998). Pericytes also secret Ang1, the main agonistic ligand for Tie2 receptor on 
EC (Gaengel, et al., 2009). Ang1/Tie2 pathway is shown to be essential for blood 
vessel maturation and stabilization. Mouse with Ang1 or Tie2 depletion died from 
cardiovascular failure as embryos (Suri, et al., 1996).  
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A second function of pericytes is to provide mechanical support and to control blood 
circulation through providing mechanical forces. Pericytes express a number of 
contractile proteins, for instance α-SMA, desmin and tropomyosin have been 
identified in pericytes in vivo or in vitro (Bergers, et al., 2005). Some research groups 
proposed that the pericytes are able to constrain blood vessels to contribute to the 
regulation of blood flow in small vessels (Rucker, et al., 2000; Bergers, et al., 2005). 
However, there is some controversy on if pericytes really act to provide contractile 
force to blood vessels, because there is a lack of direct evidence. Observation of 
pericyte contraction in vivo is a difficult issue, due to the lack of specific pericyte 
markers (reviewed by Armulik et al.) (2011).  
Besides these two traditional functions, there is an increasingly popular theory that 
pericyte further processes the ability to serve as a reservoir of progenitor cells in 
different tissues (Augello, et al., 2010).  As mentioned earlier, recent studies have 
reported that perivascular cells express MSC markers and possess multi-lineage 
differentiation potential (Crisan, et al., 2008; Covas, et al., 2008; da Silva Meirelles, 
et al., 2006; Shi, et al., 2003). As early as in 1988, it has been found that alkaline 
phosphates positive cells in the bone marrow are able to differentiate into adipocytes 
(Bianco, et al., 1988). More recently, pericytes derived from various tissues have 
been demonstrated to possess myogenic capacities (Crisan, et al., 2008). It has been 
further suggested that pericytes exhibit stem cell features and may even be 
mesenchymal stem cells (MSCs). It has been proposed that pericyte-like populations 
reside in a perivascular niche and may serve as local stem cell reservoirs (Crisan, et 
al., 2008; Zannettino, et al., 2008; da Silva Meirelles, et al., 2006; Shi, et al., 2003). It 
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is found that perivascular cells, isolated from adipose tissues by pericyte related 
markers STRO-1, CD146 or 3G5, expressed also stromal cell related markers (CD44, 
CD90, CD105, CD106, CD146, CD166, STRO-1, and alkaline phosphatase). These 
cells equally demonstrated the potential to differentiate into cells from different 
lineages (Zannettino, et al., 2008). This suggests that pericytes, besides their 
angiogenic properties, may also serve as a local stem cell source that response quickly 
to damaged tissues or growth signals in their proximity. 
The group led by Bruno Péault in Pittsburgh published the ground-breaking article in 
Cell Stem Cell in July 2008 (Crisan, et al.), where they identified NG2, CD146, 
PDGFR-β as exclusive markers for cells at perivascular location. They thus isolated 
“pericytes” from different adult and fetal tissues by sorting for CD146+ CD34- 
CD45- CD56- population. They found that this cell population has the potential to 
differentiate into myogenic, osteogenic, adipogenic, and chondrogenic lineages, 
maintains the expression of pericytic markers NG2, CD146, and αSMA, as well as 
typical MSC antigens. They equally demonstrated by immunohistochemistry that 
MSC marker expressing cells were found in perivascular locations, and that they co-
expressed CD146.  
1.3 in vitro identification methods for MSCs  
The international consensus for defining MSCs is by their three features: plastic 
adherence, marker expression, and multipotency (Dominici, et al., 2006).MSCs in 
culture are characterized by their plastic-adherent well-spread morphology (Pittenger, 
et al., 1999; Dominici, et al., 2006).  Furthermore, there is a set of markers that are 
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generally agreed upon to be expressed by MSCs. MSCs are expected to express CD90 
(Thy-1), CD105 (Endoglin), CD73, CD13 (APN) (Jiang, et al., 2002). At the same 
time, MSCs normally do not express CD11b (monocyte marker), CD45 (leukocyte 
marker), CD34 (hematopoietic stem cell marker), CD117 (c-kit, hematopoietic 
progenitor cell marker), CD19 (B cell marker), HLA-DR (antigen presenting cell 
marker), glycophorin-A, and CD31 (EC marker) (Kolf, et al., 2007; Dominici, et al., 
2006). 
1.3.1. Three MSC hallmark antigens CD90, CD105, and CD73 
CD90, CD105, and CD73 are the three MSC markers that are part of the minimal 
criteria for defining MSC proposed by the International Society for Cellular Therapy 
(ISCT) (Dominici, et al., 2006). This publication has been intensively cited as a 
standard of MSC identification in vitro. 
CD90, also named Thy-1, is an important surface glycoprotein that regulates cell-cell 
interactions (Rege, et al., 2006). MSCs are shown to express CD90 in culture 
(Pittenger, et al., 1999). It is expressed in fibroblasts, brain cells, thymocytes, T cells, 
myoblasts, epidermal cells and keratinocytes (Pont, 1987; Haeryfar, et al., 2004) . It is 
also found in activated endothelial cells, smooth muscle cells, and a restricted 
population of hematopoietic cells (Craig, et al., 1993; Haeryfar, et al., 2004). In 
fibroblasts, CD90 is found to affect cell proliferation, collagen production, and 
migration (reviewed by Rege, et al., 2006).  
CD105 (endoglin), is a dimeric protein that form part of the transforming growth 
factor-beta receptor complex (Yamashita, et al., 1994). CD105 is strongly expressed 
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in vascular EC and plays a role in angiogenesis. It is also expressed in stromal cells 
and fibroblasts, as reviewed by Fonsatti (2001).  
CD73 (ecto-5'-nucleotidase (S'-NT)) is an ecto-enzyme commonly found on the cell 
membrane which catalyzes the dephosphorylation of monophosphates (Resta, et al., 
1998). It is found to be expressed in mesenchymal stem cells as well as in 
lymphocytes (Barry, et al., 2001).  
1.3.2. MSCs frequently express CD29, CD13, CD166, and CD146 
Integrins are the major surface adhesion receptors. They consist of αβ heterodimers 
(Hynes, 1992). CD29 is the integrin β1 subunit, which are the receptors for collagen 
(α1β1, α2β1, α10β1, α11β1), laminin (α3β1, α6β1, α7β1), and RGD (α5β1, αVβ1, 
α8β1), a tripeptide present in fibronectin and vitronectin (Hynes, 2002).Most of them 
are expressed in endothelial cells (Francis, et al., 2002). Integrins β1 are equally 
found in the center nervous system and are important for cerebral angiognenesis, 
especially α5β1 (Li, et al., 2012). All four integrin β1 isoforms are expressed in 
MSCs, with β1A showing the highest expression. (Ip, et al., 2007). As reviewed by 
(Francis, et al., 2002), β1 integrins or CD29 have been shown to play an essential part 
in vascular development. Angiogenesis is haulted after inhibition of α1β1 and α2β1 
(Senger, et al., 1996). 
CD13 is a membrane bound ectopeptidase named aminopeptidase N (APN) which 
contribute to the degradation of certain proteins and peptides. Besides its enzyme 
activity, it is also involved in other cell activities, especially in the migration, 
differentiation, and angiogenesis of malignant tumor cells (Wickström, et al., 2011).  
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The expression of CD13 is found in a wide range of cell types including epithelial, 
endothelial, and fibroblast-like cells. It is also strongly expressed in stem cells. It is 
used as a differentiation marker for granulocytes and monocytes, as reviewed by 
Bauvois, et al., (2006) 
CD166, also named as activated leukocyte cell adhesion molecule (ALCAM), is a cell 
surface immunoglobulin. As its name suggests, CD166 is important for cell adhesion.  
It is expressed on hematopoietic progenitor cells, and endothelial cells, as reviewed 
by Ohneda, et al., (2001).  
CD146 or S-endo 1 is a membrane glycoprotein that is located at the cell-cell contact 
point, and is possibly involved in cell-cell adhesion and cell-matrix interaction. 
CD146 is one of the markers that interest us the most, because it is often used for 
pericyte identification for research or commercial applications. It is reported to be 
expressed in EC, smooth muscle tissues, cerebellum, hair follicles of normal tissues, 
as well as melanomas and some other malignant tissues (Shih, et al., 1994). Recent 
discoveries have shown that CD146 is found in cells that co-express pericyte markers 
such as α-SMA and 3G5 (Shi, et al., 2003). Zimmerlin and colleagues and also shown 
that CD146+/CD31- cells identifies pericytes in tissue verified by histology 
(Zimmerlin, et al., 2009). CD146 has routinely been used as a marker for pericyte 
sorting from heterogeneous populations (Péault, et al., 2007; Crisan, et al., 2008; 
Covas, et al., 2008; PromoCell). 
1.3.3. MSCs are supposed to be negative for EC markers CD144, and VEGFR2, 
and hematopoietic markers for CD45, CD34, and CD117 
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CD144, or VE-Cadherin, is the main adhesion molecule that is responsible for EC-EC 
cell junction. It is essential for the maintenance and regulation of cell-cell contacts 
and permeability of vessels. It is a specific EC marker (Vestweber, 2008).  
Vascular endothelial growth factor receptors 2 (VEGFR2), or flk-1, is the major 
regulator of VEGF’s mitogenic, angiogenic and permeability-regulation effect 
(Ferrara, et al., 2003). VEGFR2 is critical for the development of EC. It is mostly 
expressed in Vascular ECs and lymphatic ECs, while expression is also observable in 
neuronal cells, megakaryocytes and hematopoietic stem cells (Holmes, et al., 2007) 
 CD45 (leukocyte common antigen) is a common hematopoietic tyrosine 
phosphatase. It is the pan-leukocyte marker expressed in all hematopoietic cells but 
not mature erythrocytes. It is expressed in T cells and myeloid, and a subset of B cells 
(Nakano, et al., 2008). CD45 is involved in modulation of cell signaling and may 
control the immune cell response to external stimuli (Hermiston, et al., 2003). 
CD34 is a surface protein commonly used to identify and isolate hematopoietic stem 
cells, (Nielsen, et al., 2008). None of the tested cell types expressed these two 
hematopoietic markers.  
CD117, also named c-kit, is the stem cell factor (SCF) receptor. It is expressed in 
bone marrow derived hematopoietic stem cells, blood, mast cells, melanocytes, germ 
cells, neural cells, and human aortic endothelial cells, as (reviewed by Escribano, et 
al., 1998).   
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1.3.4. MSCs are not supposed to express histocompatibility antigen  HLA-DR, 
monocyte related antigen  CD11b, and B cell marker CD19 
HLA-DR, the main histocompatibility complex (MHC) class II molecule, is essential 
for antigen presentation function in immune cells and is expressed in macrophages, 
dendritic cells, B-cells, monocytes, and progenitor cells (Oczenski, et al., 2003; 
Yoshiike, et al., 1991). HLA-DR is not expressed in resting T cells. However in some 
pathological conditions and in tissue culture T cells are found to be positive for HLA-
DR, possibly due to activation (Yoshiike, et al., 1991). 
CD11b (Mac-1) are leukocyte surface proteins and belong to the class β2 of the 
integrin family (Mazzone, et al., 1995). It has been found in macrophages, monocytes 
(Springer, et al., 1979) as well as for granulocytes, natural killer cells, and a subset of 
T cells (McFarland, et al., 1992).  
CD19 is the major component of signal transduction-complex with CD21, CD81 and 
CD225, and amplifies signals from B cell surface receptor. It is an exclusive marker 
for B cells found in bone marrow and in peripheral blood. (Tedder, 2009).  
1.3.5. Functional assay for MSC characterization 
MSC is characterized by its ability to proliferate and to differentiate in vitro into 
multiple mesenchymal lineages, such as osteoblasts, adipocytes, chondrocytes, among 
others. It is thus also necessary to show that the population is homogeneous rather 
than the combination of a few cell types, each committed to a different lineage  
(Pittenger, et al., 1999). 
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1.4. Pericytes identification in vitro 
The vigorous definition of pericytes requires microscopic observation that the cells 
reside in the basement membrane of blood vessels. It has been recognized that 
“Pericytes” refer to different cell types that are found in the perivascular location. The 
location based definition often leads to confusion between pericytes and other 
perivascular mesenchymal cell populations such as SMC, fibroblasts, and MSCs. In 
practice it is also impossible to implement in in vitro conditions, and a compromised 
identification using morphology and the expression of a combination of markers is 
often used. Therefore, the characterization and identification of pericytes still remains 
a subject of research, as reviewed by Armulik, et al. (2011). Moreover, the difficulty 
to isolate a pure pericyte population makes it hard for studying the vascular formation 
process (Yamashita, et al., 2000). 
1.4.1. Markers 
Most of the pericyte markers are closely linked to the pericyte function. Some of the 
pericyte markers are molecules that are recognized to play an important role in EC-
pericyte interactions, such as surface receptors VEGFR, Tie2, and PDGFR-β. Some 
contractile proteins, for example α-SMA, desmin, and tropomyosin, are also 
commonly used as pericyte markers in vitro and in vivo.  There are also other surface 
antigens that are involved in vasculature, for example NG2 proteoglycan (Ozerdem, 
et al., 2001). 
It is worth noting that up to date, there is no single marker that can be used to identify 
pericytes. The multiple marker profile, which is usually used instead for pericyte 
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identification, is neither exclusive nor stable, and depends on the tissue type as well 
as the stage of development of the cells (Armulik, et al., 2011; Díaz-Flores, et al., 
2009; Lamagna, et al., 2006). Reviews containing lists of current and perspective 
pericyte markers can be found at (Armulik, et al., 2011; Díaz-Flores, et al., 2009) 
α-SMA is one of the markers most frequently used for pericyte identification. 
However, it has been shown that α-SMA is a late pericyte marker which is expressed 
only in differentiated pericytes with smooth muscle cell phenotype. Therefore a low 
expression of α-SMA does not necessarily mean the lack of pericytes (McDonald, et 
al., 2003; Ozerdem, et al., 2003; Nehls, et al., 1991). α-SMA has also been shown to 
be expressed in MSC derived from murine tissues at variable levels (da Silva 
Meirelles, et al., 2006) as well as in fibroblasts (Hinz, et al., 2001). 
PDGFR-β is the receptor of platelet-derived growth factor B (PDGF-B) that is 
released by EC during angiogenesis. It is expressed not only in pericytes, but also in 
stromal fibroblasts (Song, 2005). PDGFR-β plays en essential role in angiogenesis 
(Gaengel, et al., 2009; Rajkumar, et al., 2006). PDGFR-β or PDGFB knock-out in 
mice caused leaking vessels and can be lethal, with abnormal distribution of pericyte 
cells around the blood vessels. It is thus believed that PDGFR-β is essential for 
pericyte function of maintaining and stabilizing the vessels (Song, 2005; Levée, et al., 
1994; Soriano, 1994).  
NG2 (neuron-glial antigen 2), sometimes called HMW-MAA (high molecular weight-
melanoma associated antigen) in human, is a main transmembrane chondroitin sulfate 
proteoglycan. Ozerdem and colleague (Ozerdem, et al., 2001) have shown that NG2 
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is an exclusive pericyte marker in newly formed mouse microvasculature in vivo, and 
is expressed in α-SMA negative pericyte cells as well. It has also been shown that 
NG2 is expressed in cultured pericytes (Schlingemann, et al., 1990) as well as 
fibroblasts (Morgensterna, et al., 2003). Although the exact role NG2 plays in 
angiogenesis is not yet clear, it is known that it has strong affinity for basic fibroblast 
growth factor (bFGF) and PDGF-AA, and may thus be involved in cellular 
interaction (Ozerdem, et al., 2004).  
Desmin, another contractile protein, is a myogenic marker that is expressed in all 
muscle cells (Li, et al., 1991). Together with α-SMA and NG2, desmin has been cited 
as “late” or mature pericyte markers (Song, 2005). Unlike α-SMA, desmin has been 
found to be expressed by pericytes both in the developing state and in its mature state 
(Verhoeven, et al., 1988; Nehls, et al., 1992). Nehls and colleagues have proposed 
that Desmin+ and α-SMA- cells represent developing pericytes (Nehls, et al., 1992). 
It has also been proposed that Desmin+/α-SMA- cells are pericytes and Desmin-/α-
SMA+ cells are smooth muscle cells around the capillaries, and the expression of the 
two markers exclusive. Kurz and colleagues showed that both markers can be 
expressed by pericyte cells, although the α-SMA expression may appear weak in 
capillary pericytes (Kurz, et al., 2008). 
Tie2 is the receptor for Angiopoietin-1 (Ang1). Experiments showed that mice 
depleted of TIE2 died from ruptured vasculature, highlighting the critical function of 
Tie2 (Puri, et al., 1995). Tie2 has been reported to be expressed by developing 
endothelial cells (Dumont, et al., 1992) and hematopoietic cells (Puri, et al., 2003), 
while its ligand Ang1 is expressed both on EC and pericytes (Wakui, et al., 2006). 
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Recent research suggested that retinal pericytes also express Tie2 receptor which may 
contribute to the control of pericyte survival (Cai, et al., 2008). 
1.4.2. Functional assay 
The fundamental characteristic of pericytes is its ability to interact with endothelial 
cells and contribute to the microvasculature remodeling process. Co-culturing assay, 
where pericytes and EC are cultured together in conditions that mimic the in vivo 
scenario, provide an approximation for studying pericyte behavior. In vitro functional 
models permit the control of different factors and to study their effect in angiogenesis, 
for instance, growth factors, signal molecules, cell type involved, and cell-to-cell 
ratios. 
Different models exist for mimicking the in vivo process of angiogenesis. The 
simplest model is co-culture of two or more cell types in un-coated culture plates 
(Orlidge, et al., 1987). In 1980, EC were found to form spontaneously tube-like 
structure on collagen gel which resembles the in vivo EC behavior (Folkman, et al., 
1980). The common model is to culture EC on plates coated with matrix protein such 
as Matrigel
TM
 (2 D/3D model) or collagen (3 D) model (Bishop, et al., 1999; Koh, et 
al., 2008). Other in vitro models include organ-based models, for example the rat 
aortic ring assay, where a section of the rat aorta is cultured and the outgrowth of 
microvasculature can be measured (Ucuzian, et al., 2007). Another interesting assay 
involves the co-culture of ECs with smooth muscle cells (SMCs) in the form of cell 
spheroids in collagen gels (Korff, et al., 2001). The spheroids consisted of a mixture 
of ECs and SMCs. The sprouting of co-culture spheroids can thus be quantified by 
measuring the accumulative sprout length from each spheroid. 
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One of the most commonly used models is Matrigel
TM
 angiogenic assay. Matrigel
TM
 
Basement Membrane Matrix is developed by BD Biosciences. The Matrigel
TM
 is a 
decellularized, sterile, gel-like substance manufactured from the protein-rich matrix 
of a mouse sarcoma. Its composition is complex and contains different biological 
factors that may take part in the angiogenic assay. It contains matrix proteins 
including laminin and collagen, as well as a mixture of growth factors such as TGF-β, 
EGF, and FGF that are produced by the sarcoma cells. It is recommended for use in 
cell differentiation as well as in in vitro and in vivo angiogenic assays (BD, 2008) . 
Matrigel
TM
 is equally used for in vivo plug assay where it is incorporated with 
biological factors and injected into animal models. This is one of the most common in 
vivo angiogenic assay (Kleinman, et al., 2005).  
Matrigel
TM
 possess a few valuable properties which makes it a suitable model for 
angiogenesis. The most important is its ability to induce EC to form inter-connecting 
tubular networks with a lumen, whose morphology resembles very much the in vivo 
capillary structure (Figure 2). The networks are usually formed within 6 to 12 hours 
and serve as a rapid test for the pro-angiogenic or inhibitory effect of drugs and 
biological factors (Kleinman, et al., 2005).  The relatively rapid experimental process 
(within 24 hours) allows for a preliminary in vitro study of the angiogenesis process.  





To date, EC has either been cultured alone on Matrigel
TM
 to test the effect of 
pharmaceutical or biological molecules, or in co-culture with fibroblast to examine 
their interaction (Donovan, et al., 2001). Song and colleagues co-cultured endothelial 
cells with PDGFR-β positive perivascular cells on MatrigelTM and showed the co-
localization of the two cell types at 18 hours and 3 days time points. The experiment 
showed the co-localization of pericytes with EC-formed capillaries in vitro. However 
they did not verify if this is a pericyte-specific behavior by comparing the isolated 
PDGFR-β expressing cells to other mesenchymal cell types (Song, 2005). Darland 
and D’Amore (2001) have equally used a co-culture of EC with MSC on MatrigelTM, 
and have noted the formation of cord networks followed by aggregates formation at 
24 hours. They therefore concluded that MSC adopted a pericyte-like phenotype in 




Figure 2. EC form capillary-like networks 
when cultured on Matrigel
TM
. EC were seeded 
on MatrigelTM at 30,000 cells/cm2. Phase contrast 
photo taken at 12 hours after seeding. Scale bar 




2. Hypothesis and Objective 
The current methods for MSC and pericytes isolation and characterization are not 
able to answer the important question: although the isolated “pericytes” were tested 
for MSC and pericyte markers, as well as their multipotency, do these pericytes and 
MSCs maintain the pericyte related function, i.e., a role in angiogenesis and capillary 
maintenance? Also, there is a lack of studies that compare directly isolated pericytes 
and MSCs.  
We therefore hypothesize that differences between pericytes and MSCs exist, and 
they may be related to the pro-angiogenic function of pericytes, which has been rarely 
tested for on MSCs. 
In a nutshell, we propose that pericytes are not only MSCs, but furthermore 
possess characteristics that MSCs cannot substitute for.  
To verify this hypothesis, we first tested Pl-Prc, MSCs, as well as fibroblast for the 
generally accepted MSC marker profile. A typical MSC profile should show positive 
expression for MSC-related markers (CD90, CD105, CD73, CD29, CD13, CD166, 
and CD146).At the same time, the cells should be negative for endothelial specific 
markers (CD144 and VEGFR2), hematopoietic markers (CD45, CD34 and CD117), 
as well as macrophages, monocyte and B cell related markers (HLA-DR, CD11b and 
CD19).  
We believe that in order to identify whether pericytes are MSCs, it must be 
demonstrated that pericytes not only exhibit MSC marker characteristics, but is also 
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capable of differentiating into other mesenchymal lineages. We accessed the ability of 
all three cell types to differentiate in vitro into three mesenchymal lineages, namely 
osteoblasts, adipocytes, and chondrocytes .   
To verify the second part of our hypothesis, which is that pericytes demonstrate 
characteristics that are not present in common MSCs, we examined both the marker 
and functional pericyte-related characteristics of the three cell types. 
Immunocytochemistry of the pericyte-related markers, α-SMA, PDGFR-β, NG2, 
Desmin, and Tie2 was performed for all three cell types. All of the markers except for 
and Tie2 have been routinely used for identifying pericytes in vivo or in vitro, while 
Tie2 is a receptor that plays important roles in angiogenesis and that we believe may 
demonstrate some differences between pericyte and non-pericyte cell types. 
With respect to pericyte-specific function, we used the conventional Matrigel
TM
 
angiogenic assay, where pericytes have been observed to co-localize with EC-formed 
networks when seeded on the Matrigel
TM 
surface. We further observed and compared 
the EC network morphology To find potential differences in the angiogenic properties 








3.1. List of antibody 
Immunocytochemistry Antibodies 
Marker Clone Cat No.  Format Dilution Source 
Primary Antibodies 
Mature Pericyte Markers 
PDGFR-β  Y92 AB32570 Rabbit monoclonal 1:100 Abcam 
NG2  AB5320 Rabbit polyclonal 1:100 Millipore 




AB6322 Mouse monoclonal 1:100 Abcam 
Pericytes on Freshly Formed Vessels 
TIE-2 C-20 SC-324 Rabbit polyclonal 1:25 Santa Cruz 
Secondary Antibodies 
488 goat anti mouse  S34253  1:400 Invitrogen 
594 goat anti rabbit  A11072  1:400 Invitrogen 
Flow Cytometry Antibodies 




Iso FITC  G155-178 555573 FITC Mouse IgG2a κ 10μL BD Pharmigen 
Iso FITC MOPC-21 555748 FITC Mouse IgG1 κ 10μL BD Pharmigen 
Iso PE G155-178 555574 PE Mouse IgG2a κ 10μL BD Pharmigen 
Iso PE MOPC-21 555749 PE Mouse IgG1 κ 10μL BD Pharmigen 
MSC and EC Markers 
CD90 (Thy-1) 5E10 555595 FITC Mouse IgG1 κ 2.5 μL BD Pharmigen 
CD105 (Endoglin) SN6 12-1057 PE Mouse IgG1 κ 2.5 μL e-Bioscience 
CD29(FN receptor) MAR4  555443 PE Mouse IgG1 κ 10 μL BD Pharmigen 
CD146 (S-endo 1) P1H12 550315  PE Mouse IgG1 κ 10 μL BD Pharmigen 
VEGFR-2 (Flk-1) 89106 560494 PE Mouse IgG1 κ 10 μL BD Pharmigen 
CD144(VE-
cadherin) 
55-7H1  560411 FITC Mouse IgG1 κ 10 μL BD Pharmigen 
Hematopoietic Markers 
CD45  HI30 555482 FITC Mouse IgG1 κ 10 μL BD Pharmingen 
CD13 (APN) WM15 560998 PE Mouse IgG1, κ 10 μL BD Pharmingen 
CD34 581/CD34 555821 FITC Mouse IgG1, κ 10 μL BD Pharmingen 
CD73 (5’ –NT) AD2 550257 PE Mouse IgG1, κ 10 μL BD Pharmingen 
CD166 (ALCAM) 3A6 559263 PE Mouse IgG1, κ 10 μL BD Pharmingen 
CD117 (c-kit) 104D2 340529 PE Mouse IgG1 κ 10 μL BD Bioscience 
Monocyte Markers 
CD11b D12 347557 PE Mouse IgG2a, κ 10 μL BD Bioscience 
B/T Cell, Dendritic Cell markers 
CD19 HIB19 555412 FITC Mouse IgG1, κ 10 μL BD Pharmingen 
HLA-DR G46-6 556643 FITC Mouse IgG2a, κ 10 μL BD Pharmingen 




3.2. Cell Culture 
Human placenta pericytes (Pl-Prc) (PromoCell, C-12980), human mesenchymal stem 
cells (MSCs) (Lonza, PT-2501), human lung fibroblasts  (FB) (ATCC, CCL-186, 
strain IMR-90), and human umbilical vein endothelium cells (HUVEC) (Lonza, 
C2519A) were thawed and cultured until the desired passage, using their respective 
culture media, detachment kits, and standard protocols.   
 
Figure 3. Microscopic photos of cells in culture.  
Cell type 
Media Detachment kit 
Human placenta pericytes 
(Pl-Prc) (PromoCell, C-
12980) 





Human mesenchymal stem 
cells (MSCs) (Lonza, PT-
2501) 
Low Glucose DMEM 
(Gibco 10569) 
supplemented with 10% 







Human lung fibroblasts  
(FB) (ATCC, CCL-186, 
strain IMR-90) 
High Glucose DMEM 
(Gibco 10567) 
supplemented with 10% 





Human umbilical vein 






4176 EGM-2 SingleQuots 
(Lonza)  
Trysin/EDTA (Lonza, Cat. 
No. CC-5012) 
Trypsin Neutralizing 
solution (TNS) (Lonza, 
Cat. No. CC-5002) 
Table 2. Cell types used and their respective media and detachment kit 
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Pericytes (promocell) are isolated from microvessels of the human placenta. More 
specifically, they are isolated from the chorionic villi of theplacenta tissue. They are 
CD146+, CD105+, CD31-, CD34-. The cells are sold and delivered at passage 2 (p2) 
in serum –free freezing medium. Cells were thawed, cultured, and passaged according 
to the product manual (Promocell). 
MSC (Lonza) are isolated from human bone marrow. Cells were tested for their 
osteogenesis, chondrogenesis, and adipogenesis capacity. Cells were equally tested 
for their marker expression (CD105+, CD166+, CD29+, Cd44+, CD14-, CD34-, 
CD45-). The cells are sold and deliverd at passage 2 (p2). Cells were thawed, cultured 
and passaged according to the product manual (Lonza, 2011) 
In this study, the cells after the first subculturing are refered to as p+1, which is 
equivalent to passage 3 (p3). Subsequently, cells after the second subculturing are 
refered to as p+2 (p4), and so on.  
3.3. Flow Cytometry 
Each cell type was cultured in three separate culture flasks to produce three 
independent sample sets. Cells were harvested at confluence and resuspended in an 
appropriate volume of flow cytometry buffer (1% FBS in PBS or HBSS). Each 
sample would require 60,000 to 200,000 cells in 50 µl flow cytometry buffer. 50 µl of 
the well mixed cell suspension was pipetted into a pre-labeled eppendorf tube for 
each sample. The respective antibody was mixed by flicking or vortexing before 
being added to each sample. The samples were incubated for 1 hour at 4 °C in dark, 
with gentle agitation. At the end of the incubation, 500 µl of the flow cytometry 
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buffer was added per sample and well mixed. The samples were centrifuged at 200g 
for 5 minutes (4 minutes for Pl-Prc), the supernatant discarded, and the pellets 
resuspended in 500 µl of ice-chilled 1% formaldehyde. The samples were filtered 
before being transferred into centrifuge tubes (BD 352058) and used for flow 
cytometry (Cyan ADP flow cytometer, Beckman Coulter). 
For flow cytometry, the percentage of cells that showed positive staining compared to 
control is calculated. The exact gating (i.e. the fluoroscence treshold above which a 
cell is considered to be positively stained) is shown in Figure 3 to Figure 5. The 
percentage of positively stained cells is given by the number of cells with potive 
staining (compared to control) divided by total number of cells analyzed.  
3.4. Differentiation 
For osteogenesis, cells were plated in 24-well plates at 2,000 cells/well in their 
respective media, before switching on the following day to the inducing medium 
containing High Glucose DMEM (HG DMEM) containing 10% serum, 1% p/s, 100 
nM Dexamethasone, 100 µM Ascorbic Acid, and 10 mM β-glycerophosphate. 
Inducing media were changed each 3 to 4 days. After 28 days, cells were fixed in 4% 
formaldehyde at room temperature, washed with PBS, and incubated with Alizarin 
Red for 10 min for staining of calcium deposits. Wells were then washed with 
deionized water and allowed to air dry inside the fume hood.  
The seeding density (1,000 cells/ cm
2
) is optimized from the protocol provided by the 
supplier (3,100 cells/cm
2
) (Lonza, 2011; Salasznyk, et al., 2004; Schoolmeesters, et 
al., 2009). A low seeding density was chosen because it reduces peeling-off of control 
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sample from the plate, which happens frequently towards the end of the 
differentiation assay. Similar densities (1 × 10
3




) have been used 
for osteogenesis of embryonic stem cell derived MSCs (Barberi, et al., 2006). The 
reduction of seeding density does not seem to prevent osteogenesis, as accessed by 
Alizarin Red staining at the end of the 28
th
 day (Figure 7).  
For adipogenesis, cells were plated in 24-well plates at 50,000 cells/well in their 
respective media. Cells were allowed to adhere and to grow until confluency (usually 
within 24 hours), before switching on the next day to the induction medium 
containing High Glucose DMEM (HG DMEM), 10% serum, 1% p/s, 0.5 mM IBMX, 
1 µM dexamethasone, 0.2 mM indomethacin and 10 µg/ml insulin. The cells were 
cultured for 4 days in the induction medium, followed by a 3-day culture in the 
maintenance medium containing HG DMEM, 10% serum and 1% p/s. The cycle was 
repeated for 28 days and cells were fixed in 4% formaldehyde at room temperature, 
washed with PBS. The fixed cells were then incubated with Nile Red and DAPI 
solution for 30 min for staining of lipid droplets, before being washed and stored in 
PBS. 
For chondrogenesis, 5 x 10
5
 cells were centrifuged in 15 ml conical tubes to form 
pellets. The pellets were cultured in induction medium containing High Glucose 
DMEM (HG DMEM) with GlutaMax, 10% serum, 1% p/s, 0.1 µM dexamethasone, 
ITS + Premix (BD), 25 µg/ml ascorbic acid, 1x MEM Sodium Pyruvate (Gibco), 
4mM Proline, 10 ng/ml TGF-β3. The medium was changed three times per week. 
After 28 days, the pellets were fixed in 4% formaldehyde, dehydrated using  a series 
of ethanol and xylene washes, and embedded in paraffin. 5 µm sections were 
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produced using Microtome, The pellets were rehydrated by a series of xylene, ethanol 
and water washes, and then stained with Alcian Blue and Fast Red which stain for 
sulfated glycosaminoglycans and nuclei, respectively.  
Ficoll was added to both the induction and the maintenance medium. 
3.5. Immunocytochemistry (ICC) 
Cells were cultured on 24-well plates until 90% confluence and fixed with methanol. 
Fixed cells were incubated for 1 hour in 3% (w/v) bovine serum albumin (BSA) 
solution in phosphate-buffered saline (PBS). The BSA was then replaced by primary 
antibody diluted in PBS and incubated for 90 minutes at room temperature with 
gengle shaking. Subsequently, the cells were washed three times with PBS, shaking 
for 5 minutes during each wash, before incubation in antibody cocktail containing 
DAPI and the respective secondary antibodies for 30 minutes. Cells were again 
washed three times with PBS before representative photos were taken using Olympus 
IX71 inverted microscope and Olympus CP70 microscope camera. For each cell type, 
a well was incubated only with the secondary antibody, which served as the control 
sample. The brightness and contrast of the photos taken for each antibody were 
adjusted such that the control sample did not show visible staining. This is to ensure 
that there is no false positive due to unspecific staining of the secondary antibody. 
The same brightness and contrast value is used for the same antibody across different 
cell types. The antibodies used are detailed in Table 1. 





 was thawn overnight at 4 °C and seeded in pre-chilled 48-well plates at 
150 µl per well. The coated plates were allowed to settle overnight at 4 °C, before 
being transferred to 37 °C for at least 1 hour to induce polymeration of Matrigel
TM
. 
Cells were harvested, labeled with live cell tracking fluorescence (PKH67/PKH26, 
Sigma-Aldrich), protocol as detailed in section 3.7 below. Cells were then seeded in 
the Matrigel
TM
 coated plates in 250 µl of EGM medium. HUVEC was seeded at 
30,000 cells per well, and other cell types were seeded at different ratios with respect 
to HUVEC. The formation of capillary-like tube formation was imaged using 
Olympus IX71 inverted microscope and Olympus CP70 microscope camera at 4, 8, 
12 and 24 hours. The cells were fixed with 4% formaldehyde for at least 1 hour at 
room temperature and then washed and stored in PBS.  
3.7. Live Cell Labeling  
Cells were harvested and resuspended in Hank’s balanced saline solution (HBSS) 
(Gibco 14175) for cell counting. The needed number of cells were centrifuged down 
at 200g, 5 min and then resuspended in fluorescent diluent (Sigma PKH67/PKH26) at 
10
5
 cells/ 100 µl. Prepare fluorescent cocktail with 0.5 µl of fluorescent cell linker 
dye (Sigma PKH67/PKH26) per 100 µl diluent and mix well with the cell suspension 
at 1:1 (v/v). The samples were incubated at room temperature for 4 min and then 2 ml 
of Heat-Inactivated FBS (HI FBS) was added per sample. The samples were 
transferred to clean test tubes and centrifuged at 200g, 5 min and supernatant 
discarded. The pellets were washed twice by resuspending in HI FBS and 
centrifuging, before being resuspended in required media for further experiments.  
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4. Results   
Summary of marker expression profile of Pl-Prc, MSC, and fibroblast 
Markers Alternative name Pl-Prc MSC IMR-90 
MSC-related markers (flow cytometry, value in %) * 
CD90 Thy-1 90.3 ± 4.2 98.6 ± 0.8 99.31 ± 0.4 
CD105 Endoglin 97.8 ± 1.4 98.5 ± 0.8 98.7 ± 0.4 
CD73 ecto-5'-NT 98.2 ± 0.1 98.4 ± 0.5 99.4 ± 0.2 
CD29 Fibronectin receptor 98.8 ± 0.5 98.4 ± 0.6 99.7 ± 0. 1 
CD13 APN 99.2 ± 0.1 98.8 ± 0.7 92.3 ± 3.9 
CD166 ALCAM 96.6 ± 0.7 98.8 ± 0.3 99.4 ± 0.1 
CD146 S-endo 86.4 ± 0.7 94.1 ± 2.9 94.8 ± 3.6 
Hematopoietic markers (flow cytometry, value in %) * 
CD144 VE-Cadherin 0.5 ± 0.4 4.1 ± 1.6 0.0 ± 0.0 
VEGFR2 Flk-1 1.8 ± 1.6 2.5 ± 3.7 0.0 ± 0.0 
CD45 Leukocyte common antigen 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.2 
CD34   0.3 ± 0.5 1.6 ± 1.3 0.7 ± 1.2 
CD117 C-kit 0.5 ± 0.8 30.9 ± 25.4 5.0 ± 8.7 
Macrophage, monocytes and B, T cell related markers (flow cytometry, value in %) * 
HLA-DR  MHC class II molecule 0.0 ± 0.0 0.0 ± 0.0 0.5 ± 0.9 
CD11b Mac-1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
CD19   0.1 ± 0.1 0.7 ± 0.7 0.1 ± 0.1 
Pericyte-related markers (ICC) 
α-SMA α smooth muscle actin + +++ + 
PDGFR-β PDGFR-B receptor β +++ ++ + 
NG2 Neuron-glial antigen 2 ++ - - 
Desmin   ++ - - 
Tie2 Ang1 receptor + - - 
Table 3. Expression profile of Pl-Prc, MSC, and fibroblast (Flow cytometry and 
Immunocytochemistry).  
* For flow cytometry, the values indicated refer to the percentage of cells that express positively 




4.1. Pericytes displayed a typical MSC antigen expression 
profile  
4.1.1. Pl-Prc, MSCs and fibroblasts expressed the common MSC 
markers CD90, CD105, CD73, CD29, CD13, CD166, and 
CD146 
Pl-Prc, MSCs and fibroblasts were tested for common MSC markers CD90, CD105, 
CD73, and CD29 by flow cytometry. All of the three cell types were strongly positive 
for these MSC markers (Figure 4).  
All three cell types in the experiment, Pl-Prc, MSC, and fibroblast, expressed strongly 
CD90, CD105 and CD73. The only exception is that Pl-Prc expressed slightly lower 
level of CD90. The levels of expression of these three MSC markers are similar in 
MSCs and the negative control fibroblasts.  
Four more markers commonly cited to be expressed in MSCs, namely CD29, CD13, 
CD166, and CD146, were also tested for flow cytometry on all three cell types. 
Interestingly in this study, a high percentage ofPl-Prc, MSC, and FB cells showed 
apositive expression for CD146. For Pl-Prc, which were selected for CD146 
expression from placenta tissue, only about 86.4% of cells were positive for CD146. 
Additional testing was performed for Pl-Prc with an older passage (Figure 3a). The 
percentage of CD146 positive cell in pericyte population decreased drastically with 
increasing cell passage. Only 11.6% of cells of Pl-Prc p+5 (5
th
 passage of the 
PromoCell p2 placenta pericytes. Or passage 7) showed positive expression for 
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CD146, compared to 86.4% for Pl-Prc p+3 (3
rd
 passage of the stock cell, or passage 
5).  
 
Figure 4: Pl-Prc, MSC, and FB expressed MSC markers. Results from flow cytometry (FC). Dark 
grey shade represents the conjugate control while light grey shade represents the sample marker 
expression. The percentage of cells that showed a positive staining compared to the conjugate control 
is shown for each FC antigen at the top of the diagram. Averages and standard deviations are 
calculated from three independent samples. 
 
Figure 4a. Decrease in CD146 expression in Pl-Prc with passage. P+3 represents passage 5 and p+5 
represents passage 7.  
 
4.1.2. Pl-Prc, MSCs and Fibroblasts lacked the expression of 
endothelial markers and hematopoietic markers 
Two of the previous markers expressed in MSCs, CD146 and CD105, are also 
commonly expressed in EC. Therefore in order to rule out the possibility of the 
contamination of EC in the cell culture, flow cytometry for two specific EC markers 
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were performed. Two hematopoietic markers were equally tested to make sure that no 
hematopoietic cells were included in the cell culture. 
Pl-Prc, MSCs and fibroblasts did not express the endothelial cell markers CD144 and 
VEGFR2; neither did they express the hematopoietic markers CD45 and CD34.  
CD117 was absent in Pl-Plc and fibroblasts from the flow cytometry results in this 
study. It was slightly positive for MSCs. The expression of CD117 is highly variable 
for MSCs, with a standard deviation of 25.38%..  
 
 
Figure 5. Pl-Prc, MSCs, and FB lacked the expression of endothelial markers and hematopoietic 
markers.  Results from flow cytometry (FC). Dark grey shade represents the conjugate control while 
light grey shade represents the sample marker expression. The percentage of cells that showed a 
positive staining compared to the conjugate control is shown for each FC antigen at the top of the 
diagram. Averages and standard deviations are calculated from three independent samples. 
 
4.1.3. Pl-Prc, MSCs, and Fibroblasts did not express macrophage, 
monocyte, and B cell related markers 
As expected, none of the three cell types expressed the histocompatibility antigen 
HLA-DR and monocyte related antigen CD11b, and nor do they express the B cell 
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marker CD19. The percentages of cell population with positive expression for the 
three antigens are close to zero for all samples.  
 
Figure 6. None of Pl-Prc, MSCsand fibroblasts (FB) expressed the histocompatibility antigen 
HLA-DR, monocyte related marker CD11b, and the B cell markers CD11b and CD19 Results 
from flow cytometry (FC). Dark grey shade represents the conjugate control while light grey shade 
represents the sample marker expression. The percentage of cells that showed a positive staining 
compared to the conjugate control is shown for each FC antigen at the top of the diagram. Averages 
and standard deviations are calculated from three independent samples. 
 
 In summary, the antigen expression profile of the three cell type is very similar. It 
would be difficult to distinguish one cell type from another by looking at the MSC 









4.2. Pericytes demonstrated multipotent differentiation 
potential 
Pl-Prc, MSCs and fibroblasts were induced for 4 weeks in osteogenesis, adipogenesis 
and chondrogenesis media, respectively. For visualization of the differentiation assay 
results, Alizarin Red was used to stain the osteogenesis plates for calcium deposition, 
Nile Red used to stain the adipogenesis plates for lipid droplets, and Alcian Blue used 
to visualize the production of glycosaminoglycan for chondrogenesis. 
 
Figure 7. Osteoblast and adipocyte induction of Pl-Prc, MSCs and fibroblasts (FB).  Upper row: 
osteogenic differentiation was visualized with Alizarin Red which stained for calcium deposit. Scale 
bar represents 500 µm. Lower row: adipogenesis was visualized with Nile Red, which stained lipid 
droplets. Nuclei were stained with DAPI. Scale bar represents 50 µm. 
As shown in Fig. 7, all three cell types showed some level of calcification. The most 
Ca
2+
 deposit is found in Pl-Prc, followed by fibroblasts and then MSCs. Pl-Prc and 
MSCs show similar pattern of the Ca
2+
 deposit, with nodules of staining in the centre 
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and less intensive staining at the sides. Interestingly, fibroblasts were also able to 
produce mineral deposit under induction conditions. However, induced fibroblasts 
showed a different morphology, as shown by Alizarin Red staining (Figure 7). Instead 
of the typical mineral nodules as for Pl-Prc and MSCs, fibroblasts showed a more 
uniform Ca
2+
 deposit pattern with occasional patches of dark red staining, which is 
different from the patterns of proper osteogenesis. This would be discussed in more 
details in the discussion session.  
For adipogenesis, both Pl-Prc and MSCs produced rounded-up cells with lipid 
droplets. Fibroblasts, on the other hand, did not show any sign of adipogenesis. 
Adipogenesis in Pl-Prc shows a slightly different morphology from MSCs, with 
smaller lipid droplets and less regular cell shape, while MSCs produced large, round 
lipid droplets. However, most of the cells did produce lipid droplets, as opposed to 




Figure 8. chondrocyte induction of Pl-Prc, MSC, and fibroblast. Chondrogenic differentiation was 
visualized with Alcian Blue which stained for glycosaminoglycan (GAG) production. Scale bar 
represents 20.0 µm. The left panels show the induced sample while the right panels show the control 
samples.  
For chondrogenesis, Pl-Prc, MSCs and fibroblasts were cultured as pellets in 
induction media, over a period of 28 days. The induction protocol was optimized 
from current literature (Corselli, et al., 2012; Farrington-Rock, et al., 2004). Alcian 
blue was used for visualizing glycosaminoglycan (GAG), which is an indicator of 
chondrogenesis. Both MSC and Pl-Prc showed a positive Alcian Blue staining (Fig. 
8) compared to control (right panels), while fibroblast showed little difference 
between the induced (left panel) and the control (right panel) sample.  
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Therefore, Pl-Prc do demonstrate the main MSC characteristics in vitro , which 
includes the expression of a specific marker panel, as well as the ability to 
differentiate into different lineages in vitro (Dominici, et al., 2006). So far, by MSC-
related marker panel and the differentiation assay, there is no clear difference 
between Pl-Prc and MSCs. It is interesting to note that although fibroblasts are 
indistinguishable from Pl-Prc and MSC by the MSC-related marker panel, they fail to 
pass the functional assay, which is the in vitro differentiation into different lineages.  
4.3. Pl-Prc expressed pericyte-related markers that MSCs 
lacked 
Pl-Prc, MSCs and fibroblasts had a positive staining for α-SMA, which was strongest 
in MSCs.  MSCs showed a staining pattern of parallel aligned intracellular fibers in 
all cells, whereas only a proportion of Pl-Prc and fibroblasts showed a staining, which 
was either granular or showed a less pronounced pattern of intracellular fibers. 
PDGFR-β was expressed by all three cell types in this experiment, with the weakest 
staining in fibroblasts. Interestingly, the distribution of PDGFR-β staining was 
different in pericytes, showing a granular pattern around the nucleus approximately at 
endoplasmic reticulum location. MSC and fibroblast had a staining distributed over 
the whole cell body with stronger staining at cell-cell borders. Despite that, Pl-Prc’s 




Figure 9: Pl-Prc, MSCs, and fibroblasts all 
expressed pericytic markers α-SMA and 
PDGFR-β. ICC results for α-SMA (green) 
and PDGFR-β (red) for Pl-Prc, MSC, and 
fibroblast (FB) respectively. Scare bar 
represents 50 µm. The corresponding Dapi nuclear staining is shown below. 
NG2 expression is present in Pl-Prc, but not in MSCs and fibroblasts. Similar to 
PDGFR-β staining in Pl-Prc, NG2 was found principally around the nucleus 




Pl-Prc exhibited the strongest desmin expression among the three cell types. MSC 
showed a very weak staining, while fibroblasts were clearly negative for desmin 
Figure 10. NG2 expression is weak in all 
three cell types. ICC results for NG2 (red) for 
Pl-Prc, MSC, and fibroblast (FB) respectively. 
Scare bar represents 50 µm. The corresponding 




expression.  Desmin in Pl-Prc was found at the cell surface. Fiber-like staining can be 
visualized, which indicate the presence of functional desmin fibers. 
 
Figure 11: Pl-Prc showed the strongest 
expression of desmin. ICC results for desmin 
(green) for Pl-Prc, MSC, and fibroblast (FB) 
respectively. Scare bar represents 50 µm. The 
corresponding Dapi nuclear staining is shown 
below. 
Tie2 is only expressed in Pl-Prc among the three cell types. From Figure 12, it can be 
seen that the staining for Tie2 in Pl-Prc was found mostly around the nuclei, likely to 
be at the Golgi apparatus. There was no observable staining for MSCs and fibroblasts, 
even though the cell densities were similar for all the three cell types, as shown by the 
DAPI nuclear staining. 
 
Figure 12. Pl-Prc showed positive staining 
for TIE2, ICC results for Tie2 (red) for Pl-
Prc, MSC, and fibroblast (FB) respectively. 
Scare bar represents 50 µm. The 
corresponding Dapi nuclear staining is shown 
below. 
4.4. Only pericytes maintained EC-formed network in 
Matrigel
TM
 angiogenic assay 
54 
 
4.4.1.  Only EC was able to develop networks on MatrigelTM 
alone.   
 
Figure 13. Only EC formed networks when cultured alone on Matrigel
TM
. EC, Pl-Prc, MSCs, and 
fibroblasts were seeded separately at 30,000 cells per cm2 per well on MatrigelTM. Photos were taken at 
4 hours, 8 hours, 12 hours, and 24 hours after seeding, respectively. Cells were labeled with PKH26 or 
PKH67 (refer to Materials and methods 3.7 Live cell labeling). Row 1: EC monoculture (red). Row 2-
4: Pl-Prc, MSCs, and fibroblasts monoculture, respectively (green).  
First of all, a mono-culture of the different cell types was performed on Matrigel
TM
. 
Cells were seeded separately on the surface of a thin layer of Matrigel
TM
 coating. The 
seeding density is 30,000 cells per cm
2
. Among EC, Pl-Prc, MSCs and fibroblasts, 
only EC were able to form capillary-like networks, which remained stable for up to 
24 hours.. The other cell types formed cell layers, which quickly arranged into 
smaller cell aggregates. They were interconnected by single cells, and finally 
contracted into bigger cell aggregates. All happened within 24 hours, however the 
time frame was cell specific. Fibroblasts show the fastest rate of network evolution, 
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where almost no network structure managed to be formed. They are followed by that 
of Pl-Prc, and then MSCs. 
4.4.2. Pl-Prc, MSCs, and fibroblasts co-localized with EC-formed 
network  
 
Figure 14. Pericyte co-localize with EC-formed networks on Matrigel
TM
 in vitro. Left column (a 
&c) shows phase contrast photos and right column (b &d) shows cells labeled with fluorescent cell 
linker dye (as described in figure 13), where EC were labeled with red fluorescent dye and Pl-Prc 
green. (a) & (b) Pl-Prc co-localized with EC-formed tubular structure and attached themselves along 
the tubes. (c) & (d) Pl-Prc co-localized with the junction points of the EC-formed network. Photo taken 
at 12 hours after seeding on MatrigelTM. 
When EC and Pl-Prc are co-cultured on Matrigel
TM
, the Pl-Prc co-localized with EC-
formed networks and resided preferably at the junction points or along the length of 
the EC-formed vessels (Figure 14) This phenomenon is similar to what Song and 
colleague (2005) described in their work. 
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To compare the ability of Pl-Prc, MSCs, and fibroblasts to co-localize with EC-
formed vessels on Matrigel
TM
, experiments were repeated with MSC and fibroblasts 
(Figure 15).  
 
Figure 15. Pl-Prc, MSCs, and fibroblasts (green) all co-localized with EC (red) formed network 
on Matrigel
TM
.  EC were seeded in co-culture with Pl-Prc, MSCs, and fibroblasts, respectively. EC 
were seeded separately at 30,000 cells per cm2 per well on MatrigelTM. Photos were taken at 12 hours 
after seeding. Cells were labeled with fluorescent cell linker dye (as described in figure 13), where EC 
were labeled with red fluorescent dye and Pl-Prc, MSCs, and fibroblasts green. 
Surprisingly all the three cell types (Pl-Prc, MSCs and fibroblasts) are able to co-
localize with EC-formed networks. Their distributions with respect to EC are highly 
similar. They bound closely to EC-formed networks, and are either incorporated into 
or in co-localization with EC-formed tubes. They were found at the junction points as 
well as along the tubular structures. By observing the co-culture at the 12 hours time 
point, it is difficult to distinguishi between Pl-Prc, MSCs, and fibroblasts.  
4.4.3. Pl-Prc maintained the EC networks over time  
To further analyze the behavior of the different mesenchymal cell types tested, the co-
culture assay was repeated with different cell ratios and time points (Figure 16 to 
Figure 19). In contrast to the 12 hours time point co-culture experiment (Figure 15), 
here the differences between Pl-Prc and the other two cell types were much more 
pronounced. At high cell densities (EC: Pl-Prc/MSC/FB = 2:1), only Pl-Prc were able 
to maintain tubular networks even at 24 hours after cell seeding although less and 
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thicker tubes remained, whereas for MSCs and fibroblasts, the networks were totally 
contracted away at 24 hours. For lower cell densities (EC: Pl-Prc/MSC/FB = 20:1), 
the EC-Pl-Prc co-culture networks resembles the networks formed by EC alone 
(Figure 13). While for MSCs and fibroblast, the networks were quickly contracted 
into small aggregates, similar to what is observed in MSC and fibroblast 
monocultures. No network structure can still be recognized at 24 hours. In contrast 
although Pl-Prc formed similar aggregates in monoculture, they did not show the 
same behavior in co-culture with EC. This indicates that the interaction between 
pericytes and endothelial cells has an effect on pericyte behavior. 
 
Figure 16. Pl-Prc/ MSC/ FB co-culture with EC on Matrigel
TM
 4 hours after seeding.  EC were 
seeded in co-culture with Pl-Prc, MSCs, and fibroblasts at various ratios, respectively. EC were seeded 
at 30,000 cells per cm2 on MatrigelTM. Photos were taken at 4 hours after seeding. Only EC are shown 
here which were labeled with red fluorescent dye. Scale bar represents 1mm. 
At four hours after seeding, for EC and Pl-Prc co-culture, there is no clear difference 
between networks containing different concentrations of Pl-Prc. Furthermore, the 
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networks appeared to be more structured compared to the network at four hours when 
EC is seeded alone (Figure 13). 
For MSCs and fibroblasts, the cells rapidly assemble. At higher concentrations, EC 
can be seen to be contracted together, leaving only blank spaces behind. 
 
Figure 17. Pl-Prc/ MSC/ FB co-culture with EC on Matrigel
TM
 8 hours after seeding EC were 
seeded in co-culture with Pl-Prc, MSCs, and fibroblasts at various ratios, respectively. EC were seeded 
at 30,000 cells per cm2 on MatrigelTM. Photos were taken at 8 hours after seeding. Only EC are shown 
here which were labeled with red fluorescent dye.Scale bar represents 1mm. 
At eight hours after seeding, for EC in co-culture with Pr-Plc, the tubes previously 
formed on Matrigel
TM
 have completely taken shape. The morphology of the networks 
depended on the seeding density of Pl-Prc. At high Pl-Prc cell density, the network 
consisted of fewer and thicker tubes, while at low Pl-Prc densities, there were greater 
number of tubes in the networks, which resembled those in EC mono-culture on 
Matrigel
TM
.   
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For EC in co-culture with MSCs and fibroblasts, the tubes were destroyed completely 
at high MSC or fibroblast density and only large aggregates of cells remained. At 
lower densities, the tubular network was only partially present and small cell 
aggregates and fragments with discontinuous tubes appeared.  
 
Figure 18. Pl-Prc/ MSC/ FB co-culture with EC on Matrigel 
TM
 12 hours after seeding EC were 
seeded in co-culture with Pl-Prc, MSCs, and fibroblasts at various ratios, respectively. EC were seeded 
at 30,000 cells per cm2 on MatrigelTM. Photos were taken at 12 hours after seeding. Only EC are shown 
here which were labeled with red fluorescent dye. Scale bar represents 1mm 
At twelve hours after seeding, the tubes in networks of EC-Pl-Prc co-culture started to 
become less in number but thicker. At this point no break-down of the networks or 
the formation of aggregates was visible. The tubular structure at EC: Pl-Prc ratio 20:1 
appeared similar to control where EC is seeded alone after 12 hours. 
For MSCs and fibroblasts, almost all cells have contracted together and overall no 




Figure 19. Pl-Prc / MSC/ FB co-culture with EC on Matrigel
TM
 24 hours after seeding. EC were 
seeded in co-culture with Pl-Prc, MSCs, and fibroblasts at various ratios, respectively. EC were seeded 
at 30,000 cells per cm2on MatrigelTM. Photos were taken at 24 hours after seeding. Only EC are shown 
here which were labeled with red fluorescent dye. Scale bar represents 1mm 
At 24 hours, the lower EC:Pl-Prc ratios 2:1 and 5:1 showed the formation of the first  
cell aggregates. For higher ratios 10:1 and 20:1 tubes have further combined to form 
less but thicker ones. In contrast to EC controls, less detached single cells which came 
from the break-down of the tubes was observed in the culture.  
For MSCs and fibroblasts, except for EC-MSC 20:1 ratio all cells have formed 







This article sets out to test the hypothesis that pericytes are not only MSCs, but 
further possess properties that average MSCs are not able to substitute for. To this 
end, this study also aims to establish a set of in vitro assays that would be able to 
distinguish pericytes from other non-pericytic mesenchymal lineages such as MSCs 
and fibroblasts.  
The findings revealed shortcomings of relying solely on the marker profile for 
pericyte identification, and also presented new evidences for the importance of 
functional assays to delineate the complet phenotype of pericytes. This thesis throws 
light especially on the following aspects: 
5.1. The expression of MSC marker profile is not sufficient 
for distinguishing Pl-Prc, MSCs, and fibroblasts. 
Differentiation assay shows that Pl-Prc possess multi-
potent differentiation potential as MSCs do. 
The three mesenchymal cell types tested all expressed MSC hallmark markers and 
lack EC specific and hematopoietic markers, therefore meeting the marker expression 
criteria for being MSCs. However as fibroblasts are not MSCs. This proves that a 
MSC marker profile is necessary but not sufficient for confirming MSC identity of a 
cell population. A further criterion of defining MSC is their potential to differentiate 
into multiple mesenchymal lineages. As expected only pericytes and MSCs were able 
to give rise to osteoblasts, adipocytes, and chondrocytes, confirming their 




Surprisingly, from the flow cytometry result for an extensive MSC marker panel, it is 
almost impossible to distinguish between Pl-Prc, MSCs, and the negative control 
fibroblasts. Therefore, the expression of MSC-related markers is necessary but not 
sufficient to identify MSCs. 
Among the MSC-related antigens, CD146 in particular is worth noting. It is often 
used alone or in combination with other pericyte-related markers for sorting of 
pericytes from a heterogeneous population (Péault, et al., 2007; Crisan, et al., 2008; 
Covas, et al., 2008; PromoCell). However, the flow cytometry results show that Pl-
Prc, MSCs, and fibroblasts all have similar level of expression for these two markers. 
It pose question on the efficacy of using CD146in identifying pericytes from other 
cell types in vitro, especially from MSCs and fibroblasts.    
CD146, which is expressed in MSCs, ECs, and pericytes, is extensively used for 
pericyte identification and isolation (Péault, et al., 2007; Crisan, et al., 2008; Covas, 
et al., 2008). In fact the Pl-Prc used in this study were also isolated for CD146 
(PromoCell). In this study, Pl-Prc, MSCs, and fibroblasts all exhibited high levels of 
CD146 expression. Therefore we conclude that CD146 is not specific enough to 
distinguish these closely related cell types. Cell sorting using CD146 as the sole 
marker may result in a heterogeneous population rather than pure pericytes. 
Furthermore, the expression of CD146 is dynamic and passage dependent. We have 
conducted flow cytometry for later passages of Pl-Prc up to p+5 (p7), and we found 
that CD146 expression is significantly decreased with passaging. It is possible that 
CD146 is a dynamic marker and is gradually lost during cell passaging.  
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Therefore, although CD146 has been useful for isolating pericytes from tissues, it 
may not be a specific and stable marker for identification or purification of pericytes 
in vitro.   
An interesting observation for differentiation assay is that fibroblasts showed the 
ability to produced calcium deposit after induction. However, as they are not able to 
produce fat droplets under adipogenic induction conditions they are not multipotent 
and can be clearly distinguished from MSC and pericytes. The ability to deposit 
calcium under osteogenic induction conditions is well known and was shown not to 
resemble the differentiation into osteoblasts (Ducy, et al., 2000; Cho, et al., 1992; 
Querido, et al., 2012). 
It has been proposed that fibroblasts are very similar to differentiated osteoblasts. 
Their morphology in cell culture is difficult to distinguish. Furthermore, all genes that 
fibroblasts express are equally expressed in osteoblasts. However, it has also been 
point out that osteoblast, and not fibroblast, deposited minerized matrix outside the 
cell during cell culture (Ducy, et al., 2000). Cho and colleagues (1992) have shown 
that periodontal ligament fibroblasts, when induced with dexamethasone and ascorbic 
acid, are able to form mineralized matrix containing calcium deposit in immature 
form of hydroxyapatite. They have equally shown that these fibroblasts did not 
differentiate into osteoblast, and the morphology is different from mineralization of 
multi-potent stem cells in culture: the fibroblast cell body was elongated and they 
produced needle shaped crystals with highly aligned fibers, and did not resemble the 
bone matrix formed in vivo. On the other hand, cells that undergo typical osteogenic 
differentiation show minerized nodules that resembles real bone tissues, with densely 
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mineralized centers, and less minerized surrounding regions. The collagen fibers in 
the bone matrix are poorly oriented, with globular mineral deposits (Querido, et al., 
2012). In our hands, only cultures of pericytes and MSC showed calcified centers 
resembling nodules, which expanded as the differentiation assay. Fibroblast showed 
rather strongly calcified areas with sharp edges and even Ca2+ distribution, therefore 
lacking the expanding nodules. (Figure 7) Therefore we conclude that fibroblast 
rather did not differentiate into osteoblast, but this will have to be confirmed further.  
It has been noted that the lipid droplets in Pl-Prc are smaller in size compared to those 
in MSCs, while the number of cells that produced lipid droplets are greater for Pl-Prc. 
However, it is possible that since the two cell types come from different tissue of 
origin, their morphology turned out not exactly the same. In fact, it has been reported 
that among MSCs from different tissues, the adipogenic differentiation outcomes 
were different. MSCs derived from umbilical cord blood, for example, gives tiny lipid 
droplets compared to MSCs from bone marrow or adipose tissue (Rebelatto, et al., 
2008). 
To conclude, both the MSC-related marker profile as well as in vitro differentiation 
assay are not able to distinguish between a typical pericyte population (Pl-Prc) and a 
typical bone marrow MSC population. This is in agreement with current literature 
where CD146-isolated pericytes from different tissues have been shown to display 
MSC features. However, we went one step further to test if Pl-Prc and MSC share not 
only  MSC-related characteristics, but also pericytic characteristics.  
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5.2. NG2, desmin and Tie2 may serve as pericyte-specific 
markers 
The expression of two conventional pericyte markers, α-SMA and PDGFR-β, were 
not able to distinguish pericytes from MSCs in this study. The level of α-SMA 
expression in Pl-Prc is actually lower than that in MSC. These two markers are 
equally expressed in fibroblasts. Therefore, they are not really pericyte specific for in 
vitro culture.  
NG2, desmin and Tie2, on the other hand, showed an unambiguously stronger 
expression in Pl-Prc than in MSCs and fibroblast. NG2 and desmin are well known 
pericyte markers (reviewed by Díaz-Flores, et al., 2009), while Tie2 is a novel 
antigen that we have discovered to be potentially pericyte-specific.   
These three markers are the first pieces of evidence that there may be some 
differences between MSCs and Pl-Prc. MSCs and fibroblasts expressed none of the 
three markers, indicating that they may lack some pericyte features.  
While the exact role of NG2 is still unclear, desmin and Tie2 are  possibly involved in 
pericyte function.  Desmin is a contractile protein and is regarded as a late pericyte 
marker (Song, 2005). The other marker, Tie2, showed the potential of being able to 
distinguish pericytes from other cells from the mesenchymal lineage. Moreover, Tie2 
has also important functions in angiogenesis. Ang1/Tie2 is one of ligand/ receptor 
pairs that form the bases of EC-pericyte interaction (Suri, et al., 1996). Tie2 has been 
reported to be expressed by retina pericytes (Cai, et al., 2008), however it has not 
been employed for pericyte identification or isolation so far. As CD146 is not 
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selective for pericytes among other mesenchymal cells, Tie2 represents a promising 
candidate for future pericyte identification and isolation. However, further validation 
of Tie2 expression in pericytes will be needed. 
Another valuable piece of information from ICC is that the staining pattern of α-
SMA, PDGFR-β, and NG2 in Pl-Prc suggest that pericytes in this study were not 
fully activated. For α-SMA, Pl-Prc did not show staining in the form of α-SMA fibers 
as in the case of MSCs, which indicates that α-SMA has not yet assemble into 
functional form, even the protein is present in the cell. With regards to PDGFR-β, and 
NG2, it is worth noting that although both antigens are surface markers, the 
expression of these markers in Pl-Prc was not on the cell surface, but rather very 
possibly still at the endoplasmic reticulum or the Golgi apparatus. These two proteins 
have not been transferred to the cell surface and were thus not yet functional. It has 
been reported that pericyte expression of α-SMA is up-regulated in proliferating 
microbasculatures, and its in vitro expression can be up-regulated by transforming 
growth factor β1 (TGF-β1 ) (Verbeek, et al., 1994) or by removing fibroblast growth 
factor 2 (FGF-2) (Papetti, et al., 2003). It is possible that after being extracted from its 
native niche in placenta tissue, the pericyte cells have suspended some of their 
original functions and were in a “quiescent state”.  
Together with the pattern of CD146 expression, the results suggest also that the 
marker expression profile of pericytes is dynamic and may depend on the culturing 
and development state of the cells. Moreover, the marker expression for pericytes in 
in vitro culture may be significantly different from that in in vivo. 
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5.3. EC-network maintenance, not co-localization, is 
characteristic of pericytes  
The capability of pericytes to co-localize with EC networks on Matrigel
TM
 is often 
cited to be a pericyte-related characteristic. Song et al. (2005) used the combination 
of PDGFR-β/desmin/NG2/α-SMA expression and co-localization with EC networks 
on Matrigel as the criteria to judge if perivascular cells are pericytes. Darland et al. 
(2001) characterized MSC’s differentiation into pericytes through their NG2/α-SMA 
expression and their co-localization and network formation capability when co-
cultured with EC. However, we propose that co-localization with EC network on 
Matrigel
TM
 is not a pericyte-exclusive feature. By co-culturing EC with Pl-Prc, 
MSCs, or fibroblasts, we showed that all the three cell types were able to co-localize 
with EC-formed networks, and there is no observable difference in the way in which 
the cells distribute themselves. The behavior of co-localization with EC-formed 
vessels on Matrigel
TM
 is thus not sufficient for identifying pericyte in vitro.  
When the co-culture is maintained for a longer period of time, the difference in the 
extent that the network is preserved is clear. Only Pl-Prc at low cell density managed 
to maintain most of the network structure for up to 24 hours, while MSCs and 
fibroblast contracted it significantly so that no proper network could be identified 
anymore.  
5.4. A bold guess: MSCs may be pericytes that have partially 
lost their pro-angiogenesis potential 
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Despite the clear differences in their pro-angiogenic capacity, MSCs apparently share 
a large number of features with Pl-Prc. It indicates that MSCs and Pl-Prc are closely 
related populations. It is possible that both cells come from a common progenitor. 
Alternatively, one may have derived from another.  
We have shown that during culture, pericytes gradually lose some of their marker 
expression. It is natural to suppose that the pro-angiogenic capacity as well as the 
pericytic markers in MSC have been lost during development.  
It is equally possible that these features were lost due to different isolation and 
culturing methods, since pericytes are highly sensitive to the microenvironment that 
they are exposed to.  












This study has compared placenta pericytes, bone marrow derived MSCs, and 
fibroblasts in terms of the MSC-related features and pericytic features.  
Complementary to current literature, this study show that Pl-Prc are bona fide MSCs 
for their expression of MSC-related antigen panel, and their ability to differentiate 
into different lineages. At the same time, it shows the novel observation that MSCs do 
not express the pericyte related markers NG2, desmin, and Tie2.  
Furthermore, we came up with a new functional assay on Matrigel
TM
 that is sensitive 
enough to distinguish Pl-Prc from MSCs and fibroblasts. Although the short term 
effects of EC-Pl-Prc/MSC/fibroblasts are similar, a prolonged co-culture system 
showed that only Pl-Prc has the capacity to stabilized EC-formed network over an 
extended period of time, confirming their superior pro-angiogenic capacity compared 
to non-pericytic mesenchymal populations.  
Therefore, by comparing different cell populations using both marker expression and 
functional assays. we conclude that MSC markers expression and differentiation 
assay alone are not sufficient to distinguish pericyte from other mesenchymal 
populations. Pl-Prc do possess specific marker expression (NG2, desmin, and Tie2) 
and pro-angiogenic functions that MSCs do not share.  
This new Matrigel
TM
 stabilization assay may serve as a useful tool for screening 
pericytes in vitro. This assay can be used to complement the marker characterization 
of pericytes, which may be dynamic and may depend on culturing conditions. This 
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model directly accesses the cells’ ability to interact with and to maintain EC-formed 
networks on Matrigel
TM
, which is the fundamental function of pericytes.  
The major limitation of this study is the cell sources used. Commercial cells were 
used throughout this study as representative populations of Pl-Prc and MSC. 
Although both populations were isolated and maintained using state-of –the-art 
protocols, several limitation may still apply. First, although CD146+CD105+CD45- 
CD34- population from human placenta has been shown to be exclusively pericytes 
(Crisan, et al., 2008), the cells used were never tested for their in situ location in their 
tissue of origin. Secondly, as the pericytes and MSCs used come from different 
sources, it is possible that some of the differences in their marker expression and 
angiogenic properties are actually attributed to their different tissues of origin. A 
vigorous study would necessitate comparison of pericytes and MSCs from the same 
cell source. Our group has demonstrated that pericytes and MSCs isolated from the 
same bone marrow sample demonstrated different pro-angiogenic potentials through  
the MatrigelTM assay (Blocki, et al., under review), thus further validated the 
sensitivity of the MatrigelTM stabilization assay, as well as pericytes’ additional role 
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